BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and BioMarin strive to quickly develop important therapies for them.

The Company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® for mucopolysaccharidosis VI; Aldurazyme® for mucopolysaccharidosis I; and Kuvan® Tablets, for phenylketonuria.

Type
Public
HQ
San Rafael, US
Founded
1997
Size (employees)
2,293 (est)
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, US
Report incorrect company information

BioMarin Pharmaceutical Office Locations

BioMarin Pharmaceutical has offices in Indianapolis, New York, Nashville, Taipei and in 29 other locations
San Rafael, US (HQ)
770 Lindaro St
Novato, US
105 Digital Dr
Mocoa, CO
96 Cra. 9
Kronberg im Taunus, DE
28 Westerbachstraße
Hong Kong, HK
Mass Mutual Tower 38 Gloucester Rd
Dublin, IE
Saint James House Adelaide Rd
Show all (34)
Report incorrect company information

BioMarin Pharmaceutical Financials and Metrics

BioMarin Pharmaceutical Revenue

Embed Graph
BioMarin Pharmaceutical's revenue was reported to be $1.12 b in FY, 2016 which is a 25.5% increase from the previous period.
USD

Revenue (Q2, 2018)

746.3 m

Gross profit (Q2, 2018)

584.9 m

Gross profit margin (Q2, 2018), %

78.4%

Net income (Q2, 2018)

(60.9 m)

EBIT (Q2, 2018)

(69.6 m)

Market capitalization (14-Aug-2018)

18.3 b

Closing stock price (14-Aug-2018)

103.1

Cash (30-Jun-2018)

427.4 m
BioMarin Pharmaceutical's current market capitalization is $18.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

548.5 m751 m889.9 m1.1 b

Revenue growth, %

37%18%26%

Cost of goods sold

95.7 m129.8 m152 m209.6 m

Gross profit

452.7 m621.3 m737.9 m907.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

136.9 m151.6 m191.8 m176.8 m203.3 m250.5 m208.9 m236.7 m300 m279.9 m303.7 m317.4 m334.1 m373.4 m746.3 m

Cost of goods sold

28.1 m22.8 m31.2 m29.9 m32.8 m39.9 m36.7 m43.1 m51.6 m50.7 m50 m56.3 m59.5 m82.3 m161.4 m

Gross profit

108.8 m128.7 m160.6 m146.9 m170.5 m210.6 m172.2 m193.6 m248.4 m229.2 m253.7 m261.1 m274.7 m291.1 m584.9 m

Gross profit Margin, %

80%85%84%83%84%84%82%82%83%82%84%82%82%78%78%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

568.8 m875.5 m397 m408.3 m

Accounts Receivable

117.8 m144.5 m165 m215.3 m

Inventories

162.6 m199.5 m271.7 m355.1 m

Current Assets

1.1 b1.4 b1.1 b1.4 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

181.6 m639.8 m584.7 m398 m900.6 m440.7 m376.3 m270.5 m306 m707.3 m348.2 m354.9 m431.4 m474 m427.4 m

Accounts Receivable

124.7 m110.5 m122.3 m121.4 m175.7 m186.1 m148.9 m180.8 m214.2 m215.9 m230.3 m238.3 m251.9 m318.4 m363.6 m

Inventories

148.7 m176.9 m193.5 m204.4 m222.8 m237.5 m262.1 m297 m326.6 m347.4 m384.1 m429.8 m457.4 m468.2 m473.4 m

Current Assets

713.5 m1.2 b1.2 b1.1 b1.5 b1.2 b1.2 b992.8 m1.1 b1.7 b1.4 b1.5 b2.1 b2.2 b2.3 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(176.4 m)(134 m)(171.8 m)(630.2 m)

Depreciation and Amortization

47.3 m56.7 m47.2 m96.9 m

Inventories

(34 m)(37 m)(51 m)(64.5 m)

Cash From Operating Activities

(59.6 m)(73.5 m)(221.7 m)(227.8 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(53 m)(38.1 m)(33.5 m)7.4 m(67.5 m)(82 m)(90.9 m)(85.1 m)(424 b)(42.8 m)(16.3 m)(44.1 m)(60.9 m)

Depreciation and Amortization

23.6 m44.6 m

Inventories

193.5 m204.4 m222.8 m237.5 m262.1 m297 m326.6 m347.4 m384.1 m10.8 m15.5 m

Accounts Payable

(51.9 m)(33 m)
USDY, 2018

Financial Leverage

1.6 x
Show all financial metrics

BioMarin Pharmaceutical Operating Metrics

FY, 2016

Patent Applications

426

Patents Issued

1.17 k

Phase 1/2 Trials Products

2

Phase III Trials Products

2
Show all operating metrics

BioMarin Pharmaceutical Revenue Breakdown

Embed Graph

BioMarin Pharmaceutical revenue breakdown by geographic segment: 18.4% from Rest of the World , 13.3% from Latin America, 22.7% from Europe and 45.5% from United States

Report incorrect company information

BioMarin Pharmaceutical News and Updates

Report incorrect company information

BioMarin Pharmaceutical Company Life and Culture

Report incorrect company information